French Pharmacovigilance Public System and COVID-19 Pandemic.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
accepted:
12
12
2020
pubmed:
30
12
2020
medline:
15
4
2021
entrez:
29
12
2020
Statut:
ppublish
Résumé
The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to swiftly identify relevant safety signals. The French National Agency of Medicine was thus able to validate the data and convey their findings very early. This decentralized organization based on medical and pharmacological evaluation of case reports has proven to be efficient and responsive in this unique and challenging healthcare emergency.
Identifiants
pubmed: 33372244
doi: 10.1007/s40264-020-01034-y
pii: 10.1007/s40264-020-01034-y
pmc: PMC7769328
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
405-408Commentaires et corrections
Type : CommentIn
Références
Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335–44.
doi: 10.1111/joim.13089
World Health Organization. Coronavirus disease (COVID-19). Technical guidance. 2020. https://www.who.int/fr/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it . Accessed 30 Nov 2020.
Haut Conseil de la Santé Publique. Avis relatif à la prise en charge des cas confirmés d’infection au virus SARS-CoV2. 5. 2020. https://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=771 . Accessed 30 Nov 2020.
WHO R&D Blueprint. Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection. 2020. https://apps.who.int/iris/bitstream/handle/10665/330680/WHO-HEO-RDBlueprint%28nCoV%29-2020.1-eng.pdf?ua=1 . Accessed 30 Nov 2020.
de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–34.
doi: 10.1038/nrmicro.2016.81
Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–32.
doi: 10.1038/s41591-020-0968-3
Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M, et al. French Addictovigilance Network. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie. 2020;75(4):343–54.
doi: 10.1016/j.therap.2020.06.006
Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020;2(11):e698-711.
doi: 10.1016/S2665-9913(20)30276-9
Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, et al. French Network of Pharmacovigilance Centers. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 2020;75(4):371–9.
doi: 10.1016/j.therap.2020.05.002
ANSM. Plaquenil et kaletra: les traitements testés pour soigner les patients COVID-19 ne doivent être utilisés qu’à l’hôpital: point d'information. 2020. https://www.ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Plaquenil-et-Kaletra-les-traitements-testes-pour-soigner-les-patients-COVID-19-ne-doivent-etre-utilises-qu-a-l-hopital-Point-d-information . Accessed 30 Nov 2020.
Haut Conseil de la Santé Publique. Avis relatif à l’utilisation de l’hydroxychloroquine dans le COVID-19. 2020. https://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=837 . Accessed 30 Nov 2020.
US Food and Drug Administration. Press announcements. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and . Accessed 30 Nov 2020.
Micallef J, Soeiro T, Jonville-Béra AP. French Society of Pharmacology, Therapeutics (SFPT). Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie. 2020;75(4):355–62.
doi: 10.1016/j.therap.2020.05.003
Micallef J, Soeiro T, Jonvillle-Béra AP. COVID-19 and NSAIDs: primum non nocere. Therapie. 2020;75(5):514–5.
doi: 10.1016/j.therap.2020.07.008